Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded to Underperform Rating by Wolfe Research

Wolfe Research lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a peer perform rating to an underperform rating in a research note published on Tuesday, MarketBeat Ratings reports.

A number of other equities research analysts have also recently commented on the company. Scotiabank increased their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Barclays upped their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $294.50.

Alnylam Pharmaceuticals Trading Down 3.9 %

Alnylam Pharmaceuticals stock opened at $268.95 on Tuesday. The stock has a market cap of $34.69 billion, a P/E ratio of -102.65 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm’s fifty day moving average price is $274.82 and its 200-day moving average price is $233.29. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period last year, the business earned $1.15 earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.50% of the stock is owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC increased its position in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $26,000. Huntington National Bank boosted its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $29,000. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $30,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.